Furthermore, oral cancer cell lines (possessing activated oncogenic signaling) and their mortalin-compromised derivatives were subjected to molecular analyses to explore the potential of mortalin as a therapeutic target for oral cancer. This evidence concerns the gene HSPA9 and lip and oral cavity carcinoma.